Shares of Ascentage Pharma Group International (6855.HK), a biopharmaceutical company focused on developing anti-cancer therapies, surged 12.27% in Wednesday's intraday trading. The stock was on track for its biggest single-day gain in nearly five months, fueled by the company's plans to pursue a U.S. initial public offering (IPO) and list on a major U.S. stock exchange.
The Hong Kong-listed firm, backed by Japan's pharmaceutical giant Takeda Pharmaceutical (4502.T), announced on Tuesday that it is targeting a valuation of $1.75 billion through its upcoming IPO. According to the company's filings, Ascentage aims to raise $149 million by offering around 7.3 million American depositary shares (ADSs) at $20.34 each.
Ascentage's IPO plans have generated significant investor interest, as it would become the first sizable Chinese company to pursue a U.S. listing this year. The company's focus on developing innovative cancer therapies, coupled with its strategic partnership with Takeda Pharmaceutical, has likely contributed to the positive market sentiment surrounding the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.